Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 7/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017821 | 0.88 | LCK (0.56) | MAP3K14LCKROCK1MKNK1MKNK2 | |
| SCHEMBL7567370 | 0.85 | MAP3K14 (0.46) | MAP3K14LCKROCK1MKNK1MKNK2 | |
| SCHEMBL7508933 | 0.81 | LCK (0.56) | MAP3K14LCKROCK1MKNK1MKNK2 | |
| SCHEMBL7497927 | 0.80 | MAP3K14 (0.41) | MAP3K14LCKROCK1MKNK1MKNK2 | |
| SCHEMBL7499093 | 0.75 | MAP3K14 (0.37) | MAP3K14LCKROCK1MKNK1MKNK2 | |
| SCHEMBL7658448 | 0.72 | LCK (0.40) | MAP3K14LCKROCK1MKNK1MKNK2 | |
| SCHEMBL7020372 | 0.71 | LCK (0.80) | LCKMKNK1MKNK2JAK2JAK3 | |
| SCHEMBL7025399 | 0.71 | MKNK1 (0.68) | LCKMKNK1MKNK2 | |
| SCHEMBL7018158 | 0.71 | LCK (0.46) | LCKMKNK1MKNK2MAPT | |
| SCHEMBL7503109 | 0.69 | MAPT (0.50) | MAPTCRHBPCRHR2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |